Karus’s de novo-designed small molecule drugs combine targeted and immunotherapeutic mechanisms of action. KA2237, our selective PI3K-p110β/δ inhibitor, is in a Phase I clinical trial in patients with B-cell lymphoma. Our HDAC6-selective inhibitor, KA2507, is also in a Phase I trial, in patients with solid tumors. Both clinical studies are ongoing at The University of Texas MD Anderson Cancer Center, as part of our strategic collaboration which began in 2015.

To find out more about our collaboration with The University of Texas MD Anderson Cancer Center, click here

Development Programs

Lead Design
Lead Optimization
Preclinical Development
Phase I
Phase II
Follow-on, differentiated selective HDAC6 inhibitors